Genentech in $1.7bn immuno-oncology deal

27-02-2020

Sarah Morgan

Genentech in $1.7bn immuno-oncology deal

Sundry Photography / Shutterstock.com

California-headquartered biotech Genentech has agreed to pay $30 million upfront to develop immuno-oncology therapies with UK-based Bicycle Therapeutics.


Genentech, Roche, Bicycle Therapeutics, immuno-oncology, collaboration, R&D, immunotherapy

LSIPR